Research programme: fibrosis therapeutics - RedX Pharma

Drug Profile

Research programme: fibrosis therapeutics - RedX Pharma

Alternative Names: Porcupine inhibitor for fibrosis - RedX Pharma; ROCK2 inhibitor -RedX Pharma; Soft Pan-Rock inibitor - RedX Pharma

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Redx Pharma
  • Class Antifibrotics; Small molecules
  • Mechanism of Action PORCN protein inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrosis

Most Recent Events

  • 17 Oct 2017 Preclinical trials in Fibrosis in United Kingdom before October 2017 (RedX Pharma pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top